000650 仁和药业
已收盘 07-10 15:00:00
资讯
新帖
简况
仁和药业股价微涨0.91% 公司回应无乙肝新药研发计划
金融界 · 15:51
仁和药业股价微涨0.91% 公司回应无乙肝新药研发计划
走进中国药都，“老药方”邂逅智慧工厂，仁和药业焕新升级
中国网财经 · 07-09 10:02
走进中国药都，“老药方”邂逅智慧工厂，仁和药业焕新升级
仁和药业2025年一季度营收下滑20% 净利润结构调整显成效
DoNews · 07-03
仁和药业2025年一季度营收下滑20% 净利润结构调整显成效
仁和药业：2025年6月30日A股股东人数将会在公司中报中披露
证券之星 · 07-03
仁和药业：2025年6月30日A股股东人数将会在公司中报中披露
仁和药业：根据相关法律法规，股东人数不属于强制披露范畴
证券之星 · 06-16
仁和药业：根据相关法律法规，股东人数不属于强制披露范畴
每周股票复盘：仁和药业（000650）2024年度权益分派实施
证券之星 · 06-13
每周股票复盘：仁和药业（000650）2024年度权益分派实施
仁和药业：本公司联营企业成都瑞沐医药科技有限公司在研新药RM301B滴眼液产品
证券之星 · 06-09
仁和药业：本公司联营企业成都瑞沐医药科技有限公司在研新药RM301B滴眼液产品
仁和药业：我司有一款产品【仁和匠心 麦角硫因抗皱嫩肤霜】中使用了麦角硫因化妆品原料
证券之星 · 06-04
仁和药业：我司有一款产品【仁和匠心 麦角硫因抗皱嫩肤霜】中使用了麦角硫因化妆品原料
每周股票复盘：仁和药业（000650）董事会完成新一届选举及高管任命
证券之星 · 05-31
每周股票复盘：仁和药业（000650）董事会完成新一届选举及高管任命
每周股票复盘：仁和药业（000650）2024年度股东大会召开，审议通过多项议案
证券之星 · 05-24
每周股票复盘：仁和药业（000650）2024年度股东大会召开，审议通过多项议案
仁和药业：公司生产、销售较多种类和品规的中西药、原料药及健康相关产品
证券之星 · 05-21
仁和药业：公司生产、销售较多种类和品规的中西药、原料药及健康相关产品
图解仁和药业一季报：第一季度单季净利润同比减7.33%
证券之星 · 04-28
图解仁和药业一季报：第一季度单季净利润同比减7.33%
仁和药业(000650.SZ)发布一季度业绩，归母净利润1.64亿元，同比下降7.33%
智通财经 · 04-28
仁和药业(000650.SZ)发布一季度业绩，归母净利润1.64亿元，同比下降7.33%
仁和药业（000650）2024年年报简析：净利润减15.05%，盈利能力上升
证券之星 · 04-26
仁和药业（000650）2024年年报简析：净利润减15.05%，盈利能力上升
仁和药业(000650)4月18日股东户数10.74万户，较上期减少0.09%
证券之星 · 04-26
仁和药业(000650)4月18日股东户数10.74万户，较上期减少0.09%
图解仁和药业年报：第四季度单季净利润同比增146.39%
证券之星 · 04-25
图解仁和药业年报：第四季度单季净利润同比增146.39%
仁和药业：截止2025年4月10日，大约10.75万户左右
证券之星 · 04-15
仁和药业：截止2025年4月10日，大约10.75万户左右
仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%
金融界 · 03-11
仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%
仁和药业：2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划
证券之星 · 03-10
仁和药业：2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划
仁和药业最新公告：子公司获得盐酸莫西沙星滴眼液药品注册证书
证券之星 · 03-10
仁和药业最新公告：子公司获得盐酸莫西沙星滴眼液药品注册证书
加载更多
公司概况
公司名称：
仁和药业股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-10
主营业务：
仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。
发行价格：
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":5.55,"timestamp":1752131028000,"preClose":5.5,"halted":0,"volume":18716318,"delay":0,"changeRate":0.0091,"floatShares":1331000000,"shares":1400000000,"eps":0.335,"marketStatus":"已收盘","change":0.05,"latestTime":"07-10 15:00:00","open":5.5,"high":5.56,"low":5.49,"amount":104000000,"amplitude":0.0127,"askPrice":5.55,"askSize":2284,"bidPrice":5.54,"bidSize":5032,"shortable":0,"etf":0,"ttmEps":0.335,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752197400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.5,"symbolType":"stock","openAndCloseTimeList":[[1752111000000,1752118200000],[1752123600000,1752130800000]],"highLimit":6.05,"lowLimit":4.95,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"isCdr":false,"pbRate":1.21,"roa":"--","peRate":16.567164,"roe":"2.63%","epsLYR":0.35,"committee":-0.106131,"marketValue":7770000000,"turnoverRate":0.0141,"status":0,"floatMarketCap":7389000000},"requestUrl":"/m/hq/s/000650","defaultTab":"news","newsList":[{"id":"2550622675","title":"仁和药业股价微涨0.91% 公司回应无乙肝新药研发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2550622675","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550622675?lang=zh_cn&edition=full","pubTime":"2025-07-10 23:51","pubTimestamp":1752162718,"startTime":"0","endTime":"0","summary":"截至2025年7月10日收盘，仁和药业股价报5.55元，较前一交易日上涨0.05元，涨幅0.91%。仁和药业是一家以中药研发生产为主营业务的医药企业，公司产品涵盖中成药、化学药、生物制剂等多个领域。作为江西地区重要的医药企业，仁和药业在中药领域具有一定市场影响力。公司7月10日在投资者互动平台表示，目前没有在乙肝治疗方面的具体新药研发计划。数据显示，7月10日仁和药业主力资金净流入782.99万元，占流通市值的0.11%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10235151614013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0239","000650","BK0097"],"gpt_icon":0},{"id":"2550363509","title":"走进中国药都，“老药方”邂逅智慧工厂，仁和药业焕新升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2550363509","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550363509?lang=zh_cn&edition=full","pubTime":"2025-07-09 18:02","pubTimestamp":1752055320,"startTime":"0","endTime":"0","summary":"“药不到樟树不齐，药不过樟树不灵”，江西樟树市素有“千年药都”之称，有着1800多年的中医药历史。作为樟树中医药企业代表的仁和药业，近年来通过打造智慧工厂，实现了由传统制药向智能制药的转型升级。仁和的智慧化工艺技改，是中国中医药产业发展的一个缩影。在未来，仁和药业也将不断加大在科技创新方面的投入，进一步完善智慧工厂的建设，提升产品质量和服务水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709180749953c02bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709180749953c02bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["562390","BK0097","BK0188","BK0239","000650","561510"],"gpt_icon":0},{"id":"2548871137","title":"仁和药业2025年一季度营收下滑20% 净利润结构调整显成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2548871137","media":"DoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548871137?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:49","pubTimestamp":1751532543,"startTime":"0","endTime":"0","summary":"仁和药业近日披露2025年一季报，公司营业收入9.86亿元，同比下降20.36%；归母净利润1.64亿元，降幅收窄至7.33%。管理层方面，董事长杨潇2024年年薪99.95万元，较上年增长9.45%。公开资料显示，杨潇与副董事长肖正连为母子关系，二人分别主导企业战略与运营。作为江西老牌药企，仁和药业产品覆盖中西药、健康衍生品等多领域，2024年全年营收40.75亿元。此次季报数据表明，公司在收入承压背景下，正通过精细化运营调整利润结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507031650399535058a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507031650399535058a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["000860.SH","000860","000650"],"gpt_icon":0},{"id":"2548287302","title":"仁和药业：2025年6月30日A股股东人数将会在公司中报中披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2548287302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548287302?lang=zh_cn&edition=full","pubTime":"2025-07-03 15:37","pubTimestamp":1751528273,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业07月03日在投资者关系平台上答复投资者关心的问题。谢谢仁和药业回复：非常感谢您对本公司的关注与支持；非常感谢您对证券部工作的理解和认可！根据相关法律法规，为保障所有投资者能够平等获悉公司信息，公司会严格按照信息披露公平原则，在定期报告中披露对应期末时点的股东人数信息。2025年6月30日A股股东人数将会在公司中报中披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300020229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","000650","BK0097","BK0188","BK0239","399300"],"gpt_icon":0},{"id":"2543626670","title":"仁和药业：根据相关法律法规，股东人数不属于强制披露范畴","url":"https://stock-news.laohu8.com/highlight/detail?id=2543626670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543626670?lang=zh_cn&edition=full","pubTime":"2025-06-16 15:54","pubTimestamp":1750060480,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：您好陈董秘，请问，贵公司截止6月10日股东人数是多少？根据相关法律法规，股东人数不属于强制披露范畴，仅在定期报告中要求披露对应时点的数据。为保障所有投资者能够平等获悉公司信息，公司会严格按照信息披露公平原则，在定期报告中披露对应期末时点的股东人数信息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600016019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0239","BK0097","BK0188"],"gpt_icon":0},{"id":"2543550826","title":"每周股票复盘：仁和药业（000650）2024年度权益分派实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2543550826","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543550826?lang=zh_cn&edition=full","pubTime":"2025-06-14 07:34","pubTimestamp":1749857652,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘，仁和药业报收于5.61元，较上周的5.65元下跌0.71%。本周，仁和药业6月10日盘中最高价报5.75元。仁和药业当前最新总市值78.54亿元，在中药板块市值排名31/68，在两市A股市值排名1987/5150。公司公告汇总仁和药业2024年度权益分派方案已获2025年5月23日召开的2024年度股东大会审议通过。本次分派对象为截至2025年6月16日下午深圳证券交易所收市后在中国结算深圳分公司登记在册的本公司全体股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400009915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"gpt_icon":0},{"id":"2542641355","title":"仁和药业：本公司联营企业成都瑞沐医药科技有限公司在研新药RM301B滴眼液产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2542641355","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542641355?lang=zh_cn&edition=full","pubTime":"2025-06-10 07:15","pubTimestamp":1749510917,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业06月10日在投资者关系平台上答复投资者关心的问题。仁和药业回复：谢谢您的关注：本公司的联营企业成都瑞沐医药科技有限公司在研新药RM301B滴眼液产品，属于化药2.2类改良型新药，适应症为视网膜静脉阻塞性黄斑水肿；2024年，本公司获得了3.1类古代经典名方中药复方制剂二冬汤颗粒等新药的批文；同时本公司部署的清肺汤颗粒、温经汤颗粒、泻白散、宣郁通经汤颗粒等10多个经典名方项目均处于研发阶段，将陆续申报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061000004223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","159938","BK1515","000650","BK0097","BK1161","BK1574","BK0239","09939"],"gpt_icon":0},{"id":"2540903207","title":"仁和药业：我司有一款产品【仁和匠心 麦角硫因抗皱嫩肤霜】中使用了麦角硫因化妆品原料","url":"https://stock-news.laohu8.com/highlight/detail?id=2540903207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540903207?lang=zh_cn&edition=full","pubTime":"2025-06-04 15:55","pubTimestamp":1749023730,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业06月04日在投资者关系平台上答复投资者关心的问题。我司有一款产品中使用了麦角硫因化妆品原料，其用途是化妆品中的抗氧化剂；另外，本公司关联公司仁和全域（上海）大健康研究院有限公司有生物法的麦角硫因，目前是实验室产品，生产量为克级，主要用于研究食品、妆品和日用品的配方设计和相关的制备工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400020547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0188","BK0239","BK0097"],"gpt_icon":0},{"id":"2539878536","title":"每周股票复盘：仁和药业（000650）董事会完成新一届选举及高管任命","url":"https://stock-news.laohu8.com/highlight/detail?id=2539878536","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539878536?lang=zh_cn&edition=full","pubTime":"2025-05-31 17:58","pubTimestamp":1748685494,"startTime":"0","endTime":"0","summary":"截至2025年5月30日收盘，仁和药业报收于5.56元，较上周的5.52元上涨0.72%。本周，仁和药业5月30日盘中最高价报5.58元。本周关注点公司公告汇总：仁和药业完成第十届董事会选举及高管任命公司公告汇总仁和药业股份有限公司第十届董事会第一次临时会议于2025年5月26日召开，会议审议通过了多项议案：- 选举杨潇先生为公司第十届董事会董事长，肖正连女士为副董事长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053100010861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000650","BK0239","BK0097"],"gpt_icon":0},{"id":"2537169995","title":"每周股票复盘：仁和药业（000650）2024年度股东大会召开，审议通过多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2537169995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537169995?lang=zh_cn&edition=full","pubTime":"2025-05-24 10:40","pubTimestamp":1748054419,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘，仁和药业报收于5.52元，较上周的5.51元上涨0.18%。本周，仁和药业5月21日盘中最高价报5.58元。公司公告汇总仁和药业2024年度股东大会法律意见书及决议公告：会议召开日期为2025年5月23日下午13:00，地点为江西省樟树市仁和路36号公司会议室。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400010985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0188","BK0097"],"gpt_icon":0},{"id":"2537620631","title":"仁和药业：公司生产、销售较多种类和品规的中西药、原料药及健康相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2537620631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537620631?lang=zh_cn&edition=full","pubTime":"2025-05-21 09:04","pubTimestamp":1747789462,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)05月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有没有抗衰老之类的药物。仁和药业回复：谢谢您的关注！公司生产、销售较多种类和品规的中西药、原料药及健康相关产品，请您提供更为详细的抗衰老之类的药物名称。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052100006044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000650","BK0239","BK0097"],"gpt_icon":0},{"id":"2530476710","title":"图解仁和药业一季报：第一季度单季净利润同比减7.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530476710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530476710?lang=zh_cn&edition=full","pubTime":"2025-04-28 18:39","pubTimestamp":1745836769,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业2025年一季报显示，公司主营收入9.86亿元，同比下降20.36%；归母净利润1.64亿元，同比下降7.33%；扣非净利润1.02亿元，同比上升0.86%；负债率8.43%，投资收益1474.51万元，财务费用-94.23万元，毛利率36.85%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800029024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2530226214","title":"仁和药业(000650.SZ)发布一季度业绩，归母净利润1.64亿元，同比下降7.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530226214","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530226214?lang=zh_cn&edition=full","pubTime":"2025-04-28 17:31","pubTimestamp":1745832714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)发布2025年一季度报告，第一季度，公司实现营业收入9.86亿元，同比下降20.36%。归属于上市公司股东的净利润1.64亿元，同比下降7.33%。归属于上市公司股东的扣除非经常性损益的净利润1.02亿元，同比增长0.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000650"],"gpt_icon":0},{"id":"2530493172","title":"仁和药业（000650）2024年年报简析：净利润减15.05%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2530493172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530493172?lang=zh_cn&edition=full","pubTime":"2025-04-27 06:26","pubTimestamp":1745706361,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期仁和药业发布2024年年报。截至本报告期末，公司营业总收入40.75亿元，同比下降19.02%，归母净利润4.82亿元，同比下降15.05%。按单季度数据看，第四季度营业总收入9.24亿元，同比下降23.83%，第四季度归母净利润6623.4万元，同比上升146.39%。本报告期仁和药业盈利能力上升，毛利率同比增幅2.2%，净利率同比增幅11.17%。去年的净利率为13.9%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700001358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2530760144","title":"仁和药业(000650)4月18日股东户数10.74万户，较上期减少0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530760144","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530760144?lang=zh_cn&edition=full","pubTime":"2025-04-26 17:08","pubTimestamp":1745658516,"startTime":"0","endTime":"0","summary":"证券之星消息，近日仁和药业披露，截至2025年4月18日公司股东户数为10.74万户，较4月10日减少100.0户，减幅为0.09%。在中药行业个股中，仁和药业股东户数高于行业平均水平，截至4月18日，中药行业平均股东户数为5.21万户。从股价来看，2025年4月10日至2025年4月18日，仁和药业区间跌幅为0.37%，在此期间股东户数减少100.0户，减幅为0.09%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600011520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0188","BK0239","BK0097"],"gpt_icon":0},{"id":"2530168710","title":"图解仁和药业年报：第四季度单季净利润同比增146.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530168710?lang=zh_cn&edition=full","pubTime":"2025-04-26 01:25","pubTimestamp":1745601946,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业2024年年报显示，公司主营收入40.75亿元，同比下降19.02%；归母净利润4.82亿元，同比下降15.05%；扣非净利润3.35亿元，同比下降24.73%；其中2024年第四季度，公司单季度主营收入9.24亿元，同比下降23.83%；单季度归母净利润6623.4万元，同比上升146.39%；单季度扣非净利润3168.12万元，同比上升241.29%；负债率9.04%，投资收益7270.19万元，财务费用-1031.23万元，毛利率37.94%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600000582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2527846552","title":"仁和药业：截止2025年4月10日，大约10.75万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2527846552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527846552?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:54","pubTimestamp":1744707271,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)04月15日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 新年好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2025年4月10日A股股东人数是多少？谢谢仁和药业回复：谢谢您的关注，截止2025年4月10日，大约10.75万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041500025739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","000650","BK0188"],"gpt_icon":0},{"id":"2518751210","title":"仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751210","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518751210?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666708,"startTime":"0","endTime":"0","summary":"天眼查工商信息显示，近日，仁和药业股份有限公司出资800万元成立江西仁和医药投资有限公司，持股80%，所属行业为资本市场服务。资料显示，江西仁和医药投资有限公司成立于2025年3月10日，法定代表人为朱凌云，注册资本1000万人民币，公司位于宜春市，以自有资金从事投资活动，企业管理咨询，企业管理（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK0097","BK1574","BK0188","09939","159938","BK0239","BK1515","000650"],"gpt_icon":0},{"id":"2518422932","title":"仁和药业：2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2518422932","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518422932?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:51","pubTimestamp":1741611110,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业03月10日在投资者关系平台上答复投资者关心的问题。后续公司是否有回购增持计划？2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划。依据公司第二期员工持股计划方案，关于2024年度能否业绩等达标，请于2025年4月26日查阅公司2024年度报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000031739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0097","BK0188"],"gpt_icon":0},{"id":"2518216049","title":"仁和药业最新公告：子公司获得盐酸莫西沙星滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518216049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518216049?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:54","pubTimestamp":1741596856,"startTime":"0","endTime":"0","summary":"仁和药业(000650.SZ)公告称，公司子公司江西闪亮制药有限公司收到国家药品监督管理局核准签发的盐酸莫西沙星滴眼液《药品注册证书》。该药品为处方药，临床用于敏感微生物引起的细菌性结膜炎的治疗，为医保目录乙类药物。盐酸莫西沙星滴眼液以化学药品4类获批上市，标志着此产品视同通过仿制药一致性评价。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000022067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752172068225,"stockEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":-0.0029},{"period":"3month","weight":0.07},{"period":"6month","weight":0.0331},{"period":"1year","weight":0.0005},{"period":"ytd","weight":-0.0098}],"compareEarnings":[{"period":"1week","weight":0.014},{"period":"1month","weight":0.0369},{"period":"3month","weight":0.0838},{"period":"6month","weight":0.1077},{"period":"1year","weight":0.194},{"period":"ytd","weight":0.0471}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"仁和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"107400人(较上一季度减少0.09%)","perCapita":"12396股","listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","registeredCapital":"139993万元","survey":" 仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。","listedPrice":6.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}